History and current state of immunotherapy in glioma and brain metastasis
نویسندگان
چکیده
Malignant brain tumors such as glioblastoma (GBM) and brain metastasis have poor prognosis despite conventional therapies. Successful use of vaccines and checkpoint inhibitors in systemic malignancy has increased the hope that immune therapies could improve survival in patients with brain tumors. Manipulating the immune system to fight malignancy has a long history of both modest breakthroughs and pitfalls that should be considered when applying the current immunotherapy approaches to patients with brain tumors. Therapeutic vaccine trials for GBM date back to the mid 1900s and have taken many forms; from irradiated tumor lysate to cell transfer therapies and peptide vaccines. These therapies were generally well tolerated without significant autoimmune toxicity, however also did not demonstrate significant clinical benefit. In contrast, the newer checkpoint inhibitors have demonstrated durable benefit in some metastatic malignancies, accompanied by significant autoimmune toxicity. While this toxicity was not unexpected, it exceeded what was predicted from pre-clinical studies and in many ways was similar to the prior trials of immunostimulants. This review will discuss the history of these studies and demonstrate that the future use of immune therapy for brain tumors will likely need a personalized approach that balances autoimmune toxicity with the opportunity for significant survival benefit.
منابع مشابه
EMT related lncrnas’ as novel biomarkers in glioblastoma: a review article
Glioma is the most common type of brain tumor and according to the 2016 WHO classification, based on invasion level, it is divided into four categories. The most severe and invasive type is grade IV glioma or glioblastoma (GBM), which has a very poor prognosis and a survival rate of only 15 months. However, the molecular pathway of invasion in malignant glioma tumors has not yet been clearly el...
متن کاملO 25: Immunotherapy for Brain Tumor
In 1890, Coley observed that cancer patients who developed infections had smaller tumors. From this, he developed Coley’s toxin and treated tumors with injections of infectious materials. In 1960s, Mahaley used monoclonal antibodies to treat central nervous system(CNS) tumors, that research and clinical investigations in brain tumor immunotherapy became a serious undertaking. ...
متن کاملTypes of glioma brain tumors and genetic alterations in signaling pathways in them
Types of glioma brain tumors and genetic alterations in signaling pathways in them Background & Objective: Glioma is a common type of primary brain tumor originating in the glial cells that surrounds and supports neurons in the brain. These tumors arise from three different types of cells that are normally found in the brain: astrocytes, oligodendrocytes, and ependymal cells, accordingly types ...
متن کاملAssessment of Micro-vessel Density in Brain Glioma by CD105 Expression
Background& Objective: Micro-vascular proliferation is an important histological feature of brain glioma with more vascular proliferation is present in higher grades of glioma. CD 105 is expressed in new actively proliferating and immature endothelial cells in tumor environment and appears to be capable to distinguish between malignant neo-vasculature and normal vesse...
متن کاملExpression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade
Background & Objective Angiogenesis is an essential component of tumor growth. Expression of PSMA on the neo-vasculature of many solid tumors, including glioblastoma multi-form, has been determined. The pattern of expression suggests that PSMA may play a functional role in angiogenesis. Methods: expression of PSMA in dif...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 9 شماره
صفحات -
تاریخ انتشار 2017